Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCREASE: MTM for Cognitive Reserve in Preclinical Alzheimer's
NCT02849639Phase 1Completed
- Start
- Apr 2017
- Primary completion
- Apr 2021
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial (2 arms). Primary endpoints: Medication Appropriateness Index at 1 year and Trail Making Test B With the Scopolamine Patch at 1 year. Started Apr 2017; status: completed.
Beyond the preview
Go deeper on NCT02849639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02849639.